Cargando…

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?

Detalles Bibliográficos
Autor principal:	Wish, Jay B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568056/ https://www.ncbi.nlm.nih.gov/pubmed/33090128 http://dx.doi.org/10.1016/j.xkme.2020.08.002

Ejemplares similares

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Will There Be a Role for a Short-Acting Biosimilar Erythropoiesis-Stimulating Agent in US Nephrology Practice?
por: Wish, Jay B.
Publicado: (2019)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ylenia, Ingrasciotta, et al.
Publicado: (2019)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2020)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Guilty, or not guilty?: a short story of propofol abuse
por: Lee, Sangseok
Publicado: (2013)

Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China
por: Sui, Zhun, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
por: Aapro, Matti, et al.
Publicado: (2019)

Esophagitis and its causes: Who is “guilty” when acid is found “not guilty”?
por: Grossi, Laurino, et al.
Publicado: (2017)

Postoperative pneumoperitoneum: guilty or not guilty?
por: Lee, Chang Ho, et al.
Publicado: (2012)

Substitution—A Department Store Found Guilty
Publicado: (1904)

Not Guilty
por: Driscoll, W. E.
Publicado: (1870)

Dissociative Identity Disorder and the Law: Guilty or Not Guilty?
por: Kabene, Stefane M., et al.
Publicado: (2022)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Pleading guilty /
por: Turow, Scott
Publicado: (1993)

The Guilty Mind
por: Bearcroft, John S.
Publicado: (1968)

Who Are the Guilty?
por: Pearce, J. D. W.
Publicado: (1955)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?
por: Eribo, Osagie A., et al.
Publicado: (2019)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

The effects of chronic glucorticoid stimulation on erythropoiesis in Cushing syndrome
por: Strouboulis, John, et al.
Publicado: (2022)

Guilty as Charged: The Role of Undercoordinated Indium in Electron-Charged Indium Phosphide Quantum Dots
por: Stam, Maarten, et al.
Publicado: (2023)

Bench-to-bedside review: Natural killer cells in sepsis - guilty or not guilty?
por: Souza-Fonseca-Guimaraes, Fernando, et al.
Publicado: (2013)

Role of the humoral immune response during COVID-19: guilty or not guilty?
por: Yaugel-Novoa, Melyssa, et al.
Publicado: (2022)

Have we been guilty of ageism in the primary treatment of breast cancer?
por: Pritchard, K I
Publicado: (2007)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

“Killer” pathway not guilty
por: Leslie, Mitch
Publicado: (2009)

Nudges to reason: not guilty
por: Levy, Neil
Publicado: (2018)

When is asthma not guilty?
por: Al Shamrani, Abdullah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p293a6es8fah11bh5dq9did38